Treatment of chronic insomnia in elderly adults with dual orexin receptor antagonists: A systematic review and meta-analysis
Clicks: 1
ID: 313562
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #188 of 192 articles by views in Sleep & breathing = Schlaf & Atmung
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 192 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Study Objectives Chronic insomnia (CI) is common among older adults, and its management is particularly challenging due to changes in sleep architecture, multimorbidity, and increased vulnerability to adverse drug effects. Dual orexin receptor antagonists (DORAs) have emerged as a novel therapeutic class with promising efficacy and tolerability profiles. However, evidence specific to older adults remains limited. Here, we performed the first systematic review and meta-analysis specifically evaluating the efficacy and safety of DORAs in elderly patients with CI (PROSPERO CRD42024565687). Methods Randomized controlled trials were identified from MEDLINE, Scopus, and ClinicalTrials.gov. Objective polysomnographic outcomes, including Latency to Persistent Sleep (LPS), Total Sleep Time (TST), and Wake After Sleep Onset (WASO), as well as subjective sleep measures, were analyzed, along with safety outcomes. Results Ten studies met the inclusion criteria for the systematic review, with five studies contributing to the meta-analysis. The quantitative synthesis comprised 2235 patients in the experimental group and 1409 patients in the control group. Overall, compared with placebo DORAs reduced WASO and LPS while increasing TST after 1 month and 3 months of treatment. Importantly, DORAs increased sTST. Finally, daridorexant showed a favorable safety profile, whereas lemborexant and suvorexant were associated with higher rates of treatment-emergent adverse events than placebo, without an increase in serious adverse events. Conclusions Despite limited evidence, DORAs appear effective and generally safe for treating CI in the elderly, supporting their role as a valuable therapeutic option.
| Reference Key |
openalex_W7161473287
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Eleonora Rollo, Annibale Antonioni, Lamberto Manzoli, Francesco Di Lorenzo, Maria Elena Flacco |
| Journal | Sleep & breathing = Schlaf & Atmung |
| Year | 2026 |
| DOI |
10.1093/sleep/zsag135
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.